Jim Mellon
Chairman @ Juvenescence
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 41%
Last updated:
For AI agents: llms.txt
Industries Jim Mellon invests in
Stages Jim Mellon invests in
Countries Jim Mellon invests in
Round sizes
Round size
- Seed
- $536k–$20M
- Series A
- $4.6M–$47M
Investment Focus
Industry
- Biotechnology 15 (47%)
- Food and Beverage 7 (22%)
- Health Care 4 (13%)
- Biopharma 3 (9%)
- Pharmaceutical 3 (9%)
Stage
- Series A 11 (34%)
- Seed 8 (25%)
- Funding Round 5 (16%)
- Convertible Note 2 (6%)
- Pre-Seed 1 (3%)
Country
- United States 8 (25%)
- United Kingdom 6 (19%)
- Israel 2 (6%)
- Germany 2 (6%)
- Finland 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SuperMeat
|
SuperMeat is an Israeli bio-tech and food-tech company, developing a technology to create clean meat from chicken cells in a safe and controlled environment, external to the animal’s body. SuperMeat is set to revolutionize the meat industry from its core, aspiring to secure a better future for humans and animals alike. Clean meat is grown in acontrolled, sterile environment without the use of antibiotics and without any possibility of fecal contamination, such as salmonella. Clean meat will require significantly less resources for its production (99% less land, 90% less water), making it both a healthy and sustainable food source for the coming century. | $6M / Series A / May 12, 2026 | |
Meatly
|
Meatly provides cultivated meat made specifically for pets. | $14.1M / Series A / May 07, 2026 | |
Clean Food Group
|
Clean Food Group provides sustainable ‘CLEAN’ alternatives to these fats and oils, ranging from liquid oils like soybean to hard fats like palm oil, cocoa butter, and milk fat. Clean Food Group produces sustainable food ingredients that are better for our environment and health without compromising on teste or performance. | $6.1M / Seed / Apr 14, 2026 | |
BlueNalu
|
BlueNalu is a cellular aquaculture company that satisfies the global appetite for seafood in a fresh, sustainable, and humane way. It offers consumers with great tasting, healthy, safe, and trusted seafood products, that support the sustainability and diversity of the oceans. | $6M / Venture - Series Unknown / Dec 29, 2025 | |
|
BlueNalu
|
BlueNalu is a cellular aquaculture company that satisfies the global appetite for seafood in a fresh, sustainable, and humane way. It offers consumers with great tasting, healthy, safe, and trusted seafood products, that support the sustainability and diversity of the oceans. | $8M / Convertible Note / Dec 29, 2025 | |
Liberation Bioindustries
|
Liberation Labs believe that by innovating technology, It can free the world from the costs of industrialized agriculture and unlock a new era of accessible, healthy foods. The mission is to make precision fermentation by commercializing purpose-built manufacturing facilities for industrial biotech. | $31.5M / Convertible Note / Jan 30, 2025 | |
|
Liberation Bioindustries
|
Liberation Labs believe that by innovating technology, It can free the world from the costs of industrialized agriculture and unlock a new era of accessible, healthy foods. The mission is to make precision fermentation by commercializing purpose-built manufacturing facilities for industrial biotech. | $12.5M / Convertible Note / Apr 05, 2024 | |
Onego Bio
|
Onego Bio is a food ingredient company on a mission to create a more resilient food system through its product Bioalbumen®—the first non-animal egg protein with an amino acid sequence identical to the natural protein. Made through precision fermentation, Bioalbumen® matches the nutrition and functionality of traditional eggs while deliveringgreater supply stability, consistent pricing, and 90% lower environmental impact.With a proven industrial-scale process, FDA GRAS status, and technological development that advances positive unit economics, Onego Bio is addressing the $300BN egg market by helping food manufacturers meet rising demand for reliable protein without compromising on performance. From baked goods to sauces and ready-to-eat meals, Bioalbumen® fits seamlessly into existing formulations—making the transition to smarter proteins easier than ever. | $30M / Series A / Apr 02, 2024 | |
Meatable
|
Meatable is a food production company that produces guilt-free meat. Meatable is a company that creates manufactured meat using stem cell technology. By employing pluripotent stem cells, which have the potential to transform any type of cell from muscle to fat without serum, the company's method eliminates the need to remove any tissue from ananimal, allowing consumers to have sustainable food. | $34M / Series B / Aug 07, 2023 | |
|
Liberation Bioindustries
|
Liberation Labs believe that by innovating technology, It can free the world from the costs of industrialized agriculture and unlock a new era of accessible, healthy foods. The mission is to make precision fermentation by commercializing purpose-built manufacturing facilities for industrial biotech. | $20M / Seed / Dec 30, 2022 | |
| See all 32 investments → | |||
Co-Investors
About Juvenescence
Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity. Juvenescence has raised $111M to build an ecosystem and pipeline of assets targeting aging, age-related disease, and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development oftherapeutics that meaningfully extend human healthspan and eventually lifespan. A meaningful increase in lifespan in the already aging world will have profound implications on all sectors of society, and in particular healthcare, education, insurance, and leisure.The company creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions. Their work is based on a novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging.Juvenescence's goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence.
Juvenescence Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anthony Chow
VP IR
|
|||
|
Jim Mellon
Chairman
|
|||
Alexander Pickett
Managing Director
|
|||
Casey Swerner
Vice President
|
|||
Declan Doogan
Chief Medical Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Jim Mellon invest in?
Jim Mellon invests primarily in Biotechnology, Food and Beverage and Health Care startups, most often at Series A and Seed stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Jim Mellon's check size?
Jim Mellon typically joins rounds of $536k–$20M at Seed and $4.6M–$47M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Jim Mellon participates in.
When did Jim Mellon last invest?
The most recent investment recorded for Jim Mellon closed in May 2026. Shizune tracks 32 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
